282 results about "Proliferation activity" patented technology

The invention discloses a bran coat polypeptide GR-12 with an immunoregulation function and an application of the bran coat polypeptide GR-12, and the amino acid sequence of the bran coat polypeptide is Gly-Gln-Pro-Trp-Pro-Pro-Ala-Ser-Phe-Ala-Cys-Arg (GQPWPPASFACR, which is called GR-12 for short). Experiments find that the GR-12 can significantly enhance the proliferation activity and phagocytic activity of macrophages RAW264.7 and promote the macrophages RAW264.7 to secrete cytokines; meanwhile, it is found that the GR-12 can significantly enhance the immunomodulatory function of an immunosuppressive mouse induced by cyclophosphamide, specifically, the body weight, thymus index and spleen index of the immunosuppressive mouse are significantly recovered; and the secretion of cytokines and immune globulins in mouse serum is obviously increased. The bran coat polypeptide GR-12 is expected to be further researched and developed into a related medicine product with an immune regulation function, and has a wide application prospect.

The invention discloses recombinant human I-type collagen and application thereof. The amino acid sequence of the recombinant human I-type collagen is as shown in SEQ ID No: 2. The recombinant human I-type collagen has good cell proliferation promoting activity, cell migration promoting activity and cell adhesion promoting activity (superior to full-length recombinant human I-type collagen or commercially available human collagen) and is easy to produce. The recombinant human I-type collagen can be expected to have the effects of whitening, moisturizing, relieving and repairing, and can be applied to the fields of cosmetics, external medicines, skin care products, health care products, tissue engineering materials, medical instruments and the like.

The invention belongs to the technical field of recombinant protein, and particularly relates to recombinant human fibronectin as well as an expression method and application thereof. The recombinant human fibronectin provided by the invention selects a fibronectin core functional domain III9-10 / III12-14, the core functional domain III9-10 / III12-14 is modified and transformed to obtain an encoding gene, and the encoding gene is transferred into escherichia coli and expressed to obtain the recombinant human fibronectin. The obtained recombinant human fibronectin has good stability, proliferation promoting activity and cell migration promoting capacity, can be applied to skin care products or cosmetics, and has important use value and practical significance.

The invention provides application of a turbellarian worm extract in preparation of a product for promoting wound healing, a biological agent for promoting the proliferation activity and / or migration ability of fibroblast NIH3T3, a biological agent for improving the wound healing rate and the decrustation time and a biological agent for improving the collagen fiber deposition type in the wound healing process. The biological preparation is used for promoting regeneration of skin appendage organs in the wound healing process. Wherein the extraction of the turbellarian worm extract comprises the steps of turbellarian worm cleaning, tissue crushing, alcohol extraction, centrifugal separation and concentration drying. The turbellarian worm extract has good capacity of promoting wound healing, and has the effects of effectively improving skin wound healing efficiency, shortening decrustation time, inhibiting scar formation in the wound healing process, promoting regeneration of skin appendage organs in the wound healing process and the like.

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The present invention discloses the application of liver cancer cell ferroptosis inducer miR‑11085‑5p in the preparation of liver cancer treatment drugs, and innovative applications in the field of liver cancer treatment, specifically to the application of liver cancer cell ferroptosis inducer miR‑11085‑5p in the preparation of liver cancer treatment drugs. The present invention adopts lentiviral transfection technology to synthesize miR‑11085‑5p in vitro, and introduce it into liver cancer cells, and effectively induce liver cancer cells to undergo ferroptosis by precisely regulating the key signaling pathway of intracellular AMPKα / Nrf2, significantly inhibiting its proliferation activity. Therefore, for the disadvantages of low efficiency, large side effects and easy recurrence and metastasis of existing treatment methods for liver cancer, the miR‑11085‑5p provided by the present invention may become a biological preparation for the treatment of liver cancer, with potential drug development value, and provide a new solution for the treatment of liver cancer.

The invention discloses a breast adenoma B3 type source cell strain as well as construction and application thereof, the breast adenoma B3 type source cell strain is named as human breast adenoma cell Hthy2301 Homo sapiens and is preserved in China Center for Type Culture Collection on March 14, 2024, and the preservation number is CCTCC NO: C202478. The human thymoma cell line is stable in character, can be passaged in vitro for a long time, and has high proliferation activity. The human thymoma cell line disclosed by the invention can be used as an effective cell model, and a new experimental model can be provided for deeply researching the occurrence, development and transfer mechanisms of thymoma, the drug resistance mechanism, drug screening, drug effect evaluation and the like.

The invention discloses a method for fermenting recombinant humanized collagen by using escherichia coli and application of the recombinant humanized collagen, and belongs to the field of collagen. The amino acid sequence of the prepared recombinant humanized III-type collagen is shown as SEQ ID NO.4-7, the recombinant humanized III-type collagen is formed by connecting a plurality of repetitive units of natural collagen in series and has the advantages of being good in biocompatibility and high in safety, in addition, the nucleotide sequence for coding the recombinant collagen is designed according to the codon optimization theory, and the recombinant humanized III-type collagen has the advantages of being good in biocompatibility and high in safety. And carrying out fermentation expression on escherichia coli to obtain the recombinant humanized III-type collagen. The humanized III-type collagen can significantly improve the cell adhesion activity and proliferation activity, and can be widely applied to the fields of food, cosmetics, health care products, medical instruments and the like.

The invention discloses a novel PARP / CK2 double-target kinase inhibitor small molecule as well as a pharmaceutical composition and application thereof, the small molecule takes benzofuran pyrimidone as a parent drug effect ring and a benzene ring as a connector in drug design, and is coupled with a 1-amino-2-methylisothiourea group, so that the novel PARP / CK2 double-target kinase inhibitor is obtained. The compound has good inhibitory activity on exogenous PARP enzyme, exogenous CK2 alpha enzyme and proliferation activity of various cancer cells, and can be used for preparing antitumor drugs. # imgabs0 #

The invention discloses a biological composite material as well as a preparation method and application thereof. The biological composite material comprises a decellularized biological amnion, mesenchymal stem cells and polypeptide hydrogel. In the polypeptide hydrogel, the sequence of the polypeptide is IGSRVGDRGDS. The biological composite material can effectively promote cell growth at a thin endometrial injury position, endometrial cell proliferation activity is higher, new vessel production related gene regulation activity is enhanced, fibrosis caused by the endometrial injury is well inhibited, re-adhesion after an intrauterine adhesion separation operation is prevented, and a good application prospect is achieved. The fertility is obviously improved, and the pregnancy rate is increased.

The invention relates to the technical field of molecular biology, and particularly discloses application of miR-615 in ovarian granular cells. The miR-615 is applied to any one of the following items: preparing a product for promoting the activity and / or proliferation of ovarian granular cells; preparing a product for promoting generation of estradiol and / or progesterone; preparing a product for promoting the expression of the 3 beta-HSD and / or StAR gene; preparing a product for inhibiting ACSL4 gene expression; and preparing a product competitively combined with the lnc-GAM. According to the invention, porcine ovarian granular cells are used as a material, the expression level of lnc-GAM-miR-615 / ACSL4 regulatory axis is up-regulated or down-regulated in the porcine ovarian granular cells by using gene overexpression and interference technologies, and the expression of the lnc-GAM-miR-615 / ACSL4 regulatory axis is determined by detecting cell proliferation activity, hormone secretion level and apoptosis gene expression in combination with a dual-luciferase reporter gene test. And the regulation effect of lnc-GAM mediation on the apoptosis of the porcine ovarian granular cells is researched.

The invention relates to the technical field of biological medicine, in particular to a chronic disease treatment composition based on mesenchymal stem cells and a preparation method thereof, and the chronic disease treatment composition comprises the mesenchymal stem cells; the mesenchymal stem cells are adipose mesenchymal stem cells, dental pulp mesenchymal stem cells and bone marrow mesenchymal stem cells. According to the invention, the culture medium of the adipose-derived mesenchymal stem cells is improved, and the prepared adipose-derived mesenchymal stem cells have higher proliferation activity. Meanwhile, through experimental tests, the adipose-derived stem cells can inhibit proliferation of the prostatic hyperplasia epithelium BPH-1 cells and remarkably promote apoptosis of the prostatic hyperplasia epithelium BPH-1 cells, a new direction is provided for treatment of prostatic hyperplasia, and the adipose-derived stem cells have huge application value.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

The present invention discloses an application of highly active human umbilical cord mesenchymal stem cells. HA-MSCs were isolated from human umbilical cord tissue using TeSR-E8 containing 5% CloneR and LN521-Coated culture flasks, and a technical system for HA-MSC isolation, expansion, and cryopreservation was established. Compared with conventionally cultured MSCs, the HA-MSCs prepared by the present invention have higher proliferation activity, smaller size, a higher nuclear-cytoplasmic ratio, and highly express embryonic stem cell-associated marker antigens SOX2, Nanog, and OCT4. They have the potential to differentiate into neural, myocardial, and hepato-intestinal progenitor cells derived from the three germ layers and possess excellent anti-aging activity.

Provided herein are compounds (e.g., compounds of Formula (I) or Formula (II)), their mechanism of action, and methods of modulating proliferation activity, and methods of treating diseases and disorders using the compounds provided herein (e.g., compounds of Formula (I) or Formula (II)).

The invention belongs to the technical field of biological medicines, and particularly relates to a recombinant polypeptide for improving the activity of bone marrow mesenchymal stem cells and application of the recombinant polypeptide. The amino acid sequence of the recombinant polypeptide is as shown in SEQ ID NO.3. The recombinant polypeptide is obtained by integrating an extracellular matrix amino acid sequence and a heparin amino acid sequence. The recombinant polypeptide provided by the invention can promote the expression of the Ki67 gene and improve the proliferative activity of the bone marrow mesenchymal stem cells, also has the effect of inhibiting the replicative aging of the bone marrow mesenchymal stem cells, and has a wide application prospect.

The invention discloses dipeptide hydrogel and application thereof as a cell culture medium, and belongs to the field of material science. According to the invention, the dipeptide hydrogel is designed and assembled, and the dipeptide hydrogel is prepared by the following steps: carrying out self-assembly on phenylalanine dipeptide modified by 9-fluorenyl methoxy carbonyl protecting group (Fmoc), and then adding tetracarboxyl phenyl porphyrin (TCPP) and distearoyl phosphatidyl ethanolamine (DSPE) for co-assembly. When the dipeptide hydrogel prepared by the invention is applied as a cell culture medium, the proliferation activity of cultured cells can be improved, so that the growth speed and density of the cells are improved, and the dipeptide hydrogel has good biological safety. The possibility is provided for promoting the high-level development of the cell culture field.

The invention relates to the technical field of cartilage construction, in particular to an injectable tissue engineering cartilage in-vitro construction method which comprises the following steps: S1, micro-ecological cartilage environment simulation design; s2, self-assembly of the stent and space-time guidance; and S3, constructing a reversible tissue-degradation platform. A tissue engineering system highly simulating a natural cartilage microenvironment is constructed through the technology of combining bionic design and dynamic regulation and control, the proliferation activity and functional differentiation efficiency of cartilage cells can be effectively improved, and meanwhile, by means of intelligent support design and a growth factor delivery system, the tissue engineering system can be applied to the field of cartilage tissue engineering. Accurate release of factors and cell navigation are realized; the dynamic repair technology is combined with the non-contact mechanical stimulation and immune regulation strategy, it is ensured that transplanted tissue can be continuously generated and fully integrated with host tissue, the problems of immunological rejection or insufficient stent degradation and the like are solved, the success rate and long-term stability of cartilage regeneration are remarkably improved, and the method has good clinical application prospects.

The invention provides a culture method for improving proliferation activity and factor secretion of mesenchymal stem cells, and belongs to the technical field of cell culture, the mesenchymal stem cells are cultured in a low-oxygen environment, and the continuous proliferation, division and clone formation capabilities of the mesenchymal stem cells are improved through low-oxygen induction culture, so that the proliferation activity and factor secretion of the mesenchymal stem cells are improved. Compared with the prior art, the method has the advantages that the expression of the mesenchymal stem cells on pluripotent related genes, angiogenesis related genes and immunoregulation related genes is improved, the secretion amount of related factors is increased, the specific surface marker genes of the mesenchymal stem cells are not influenced, and the application prospect is wide. And the heterogeneity and the homogeneity of the cell population are not influenced.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 2, 4-disubstituted quinazoline derivative as well as a preparation method and application thereof. According to the invention, a series of 2, 4-disubstituted quinazoline derivative micromolecular ligands capable of acting on telomere G4 are developed on the basis of a quinazoline skeleton. The 2, 4-disubstituted quinazoline derivative disclosed by the invention has certain telomere G4 stability and telomere G4 binding capacity, better anti-tumor cell proliferation activity, low toxicity, higher cell membrane permeability and certain oral bioavailability, in addition, the 2, 4-disubstituted quinazoline derivative disclosed by the invention can activate congenital immune response of tumor cells, and can be used for preparing anti-tumor drugs. The compound has a wide prospect when being applied to preparation of anti-tumor drugs.

The present application relates to a kind of purine derivatives as the use of NSD2 and NSD3 inhibitor, the structural formula of the derivative is as shown in formula (I) or formula (II).The compound shows good NSD2, NSD3 inhibitory activity, can effectively reduce the methylation level of H3K36 in cell, and cause the reduction of cell proliferation activity of NSD2, NSD3 high expression tumor cell strain.

The invention discloses application of eleutheroside E in preparation of a medicine for preventing or treating hepatic fibrosis, and belongs to the technical field of biological medicine. The chemical name of the eleutheroside E is 4-[(1R, 3aS, 4S, 6aR)-4-[4-(beta-D-glucoside oxygen group)-3, 5-dimethoxy phenyl] tetrahydro-1H, 3H-furo [3, 4-c] furan-1-yl]-2, 6-dimethoxy phenyl-beta-D-glucoside, and the molecular formula of the eleutheroside E is C34H46O18. Researches find that the eleutheroside E has a remarkable effect of preventing or treating hepatic fibrosis diseases, does not have remarkable hepatotoxicity, and can be used for preparing the medicine for preventing or treating hepatic fibrosis. Cell experiment results show that the eleutheroside E can significantly reduce the proliferation activity of mouse hepatic stellate cells JS-1 and inhibit hepatic stellate cell activation, presents dose dependence and can be used for preparing the medicine for preventing or treating hepatic fibrosis.

The invention discloses a corrosion-resistant and collagen-functionalized magnesium-based metal coating and a preparation method of the corrosion-resistant and collagen-functionalized magnesium-based metal coating. Belongs to the technical field of biomedical material preparation. The preparation method comprises the following steps: firstly introducing hydroxyl into the surface of the magnesium alloy through alkali treatment, then sequentially dipping the magnesium alloy into a solution A and a solution B containing specific copolymers, drying to obtain an anti-corrosion coating, and finally coating with a recombinant humanized collagen solution. The copolymer A in the solution A and a magnesium substrate form a firm Si-O-Mg covalent bond through a silane coupling agent, and the fluorine-containing copolymer B in the solution B is tightly combined with a bottom layer through self-assembly, so that a super-hydrophobic anti-corrosion barrier with a stable structure and strong adhesion is constructed. The outermost collagen layer endows the magnesium alloy material with excellent endothelial cell adhesion and proliferation promoting activity. The multi-layer composite coating structure effectively solves the problems that magnesium alloy degradation is too fast, and an existing coating is weak in binding force and lacks biological functions, and has wide application prospects in implantable medical devices such as intravascular stents.

The invention discloses a preparation method of a three-dimensional umbilical cord mesenchymal stem cell exosome and application of the three-dimensional umbilical cord mesenchymal stem cell exosome in the fields of medicines and medical beauty. The preparation method comprises the step of amplifying umbilical cord mesenchymal stem cells (UC-MSCs) by adopting a three-dimensional culture system. Experiments show that IGF-1, EGF, VEGF, TGF-beta, PDGF, FGF and the like in the exosome subjected to three-dimensional culture are beneficial to skin repair and oxidation resistance, and the content of cell active factors for promoting collagen secretion is remarkably increased. The umbilical cord mesenchymal stem cell exosome significantly improves the fibroblast proliferation activity, and UV-induced skin fibroblast damage model construction and function verification experiments also prove that the exosome can promote the HA level recovery of damaged skin fibroblasts. The invention provides an efficient and safe biological material for tissue repair.

The invention belongs to the technical field of medicines, and particularly relates to bletilla striata polysaccharide hydrogel as well as a preparation method and application thereof. The BSP-MA / HA-NB hydrogel is prepared by screening the variety, dosage and preparation process of each component in the hydrogel, and the hydrogel is prepared from the following raw materials: methacrylated bletilla striata polysaccharide, o-nitrobenzaldehyde modified hyaluronic acid and the like. The adhesive property and the mechanical property of the hydrogel are obviously improved; the long-acting slow-release effect of the medicine components is achieved, the proliferation activity and migration ability of the bone marrow mesenchymal stem cells are promoted, and the bone marrow mesenchymal stem cells have good application prospects in the aspect of bone defect repair treatment.

The invention relates to the technical field of biological medicines, and provides application of ADRM1 gene / protein in preparation of a medicine for treating osteosarcoma. When the ADRM1 gene / protein is applied to the preparation of the medicine for treating osteosarcoma, the proliferation, migration and invasion capabilities of tumor cells can be remarkably inhibited, so that the occurrence and development of osteosarcoma are delayed. The expression of the ADRM1 is knocked down through an shRNA intervention technology, the mRNA and protein level of the ADRM1 in 143b and U2OS osteosarcoma cell lines can be remarkably reduced, the short-term proliferative activity and the long-term clone forming ability of the ADRM1 are further inhibited, and the migration and invasion characteristics of cells are effectively weakened. The growth of a tumor body formed after a nude mouse is inoculated with 143b osteosarcoma cells knocking down ADRM1 is obviously slowed down, and the expression of a cell proliferation marker KI-67 in the tumor body is reduced, which indicates that the ADRM1 gene / protein also plays a key regulation role in the in-vivo growth process of osteosarcoma.

The invention discloses a synthetic method of a C1-triazole oridonin derivative and an anti-tumor application of the C1-triazole oridonin derivative. The invention provides a synthetic method of the C1-triazole oridonin derivative, which comprises the following steps: carrying out four-step reaction to obtain an oridonin analogue containing an azide group at the C1 site, and catalyzing by cuprous iodide to obtain the C1-triazole oridonin derivative with the azide group at the C1 site, thereby obtaining the C1-triazole oridonin derivative with the azide group at the C1 site and the oridonin analogue with the azide group at the C1 site. According to the method, alkyne compounds containing different substituent groups react with C1-triazole oridonin to synthesize the C1-triazole oridonin derivative, the method is mild in condition and rapid in reaction, large-scale preparation of the C1-triazole oridonin derivative can be achieved, and the method is suitable for large-scale production of the C1-triazole oridonin derivative. Meanwhile, the C1-triazole oridonin derivative synthesized by the invention can be used for effectively inhibiting the proliferation activity of tumor cells and has a relatively good inhibition effect on MCF-7 cells and A549 cells.

The present invention relates to an isoindolinone derivative, a preparation method, a pharmaceutical composition and an application. The derivative is a compound of formula I or a pharmaceutically acceptable salt of the compound of formula I, wherein Ra is one of a substituted or unsubstituted aryl, a substituted or unsubstituted C1-C6 alkyl; Rb and Rc are each one of a substituted or unsubstituted C1-C6 alkyl. Compared with the prior art, the isoindolinone derivative in the present invention has a novel structure, has significant anti-cancer cell proliferation activity, and the activities of multiple compounds are superior to those of doxorubicin.

An N-heterocycle-containing boric acid compound and a preparation method and application thereof are provided. The preparation method adopts 3-bromo-1-p-tosyl-1H-pyrrolo[2, 3-b]pyrimidine as a raw material to generate (3-((5-chloro-4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)boric acid by three steps of reaction. The (3-((5-chloro-4 (1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)boric acid has good inhibition effect on the proliferation activity of brain glioma, which is proven by cell experiments.

The invention relates to the field of chemical pharmacy, in particular to an aryl ketone derivative and furazan spliced conjugate as well as a preparation method and application thereof. The structural formula of the conjugate spliced by the aryl ketone derivative and the furazan is as shown in any one of formulas I-V: # imgabs0 # imgabs1 #. A coumarin skeleton is opened, and the conjugate spliced by the aryl ketone derivative and the furazan is designed and synthesized. The aryl ketone derivative and furazan combined conjugate disclosed by the invention is novel in structure, has the effect of highly selectively inhibiting the proliferation activity of P-gp overexpression drug-resistant tumor cells, and provides a new thought and direction for overcoming the multidrug resistance of the tumor cells caused by P-gp overexpression.